RESTASIS MULTIDOSE 0.05% EYE
FDA nonproprietary name: cyclosporine
For 5.5 mL
Pharmacies pay
$617.77 filed
5.5 × $112.32159 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$615.65 filed
5.5 × $111.93625 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
1.0× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Restasis Multidose” / “Cyclosporine” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$715.44 estimated
$617.77 + $92.67 (15%) + $5.00 fee per fill = $715.44
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
RESTASIS MULTIDOSE 0.05% EYE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as cyclosporine, under the trade name “Restasis MultiDose”.
FDA gives its dosage form as emulsion and its route as ophthalmic.
The labeler, the company named on the label, is Allergan, Inc.
FDA’s Established Pharmacologic Class for it is Calcineurin Inhibitor Immunosuppressant.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00023-5301-05.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $617.77 for 5.5 mL (5.5 × $112.32159 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
The NDC
- 00023-5301-05 · Allergan, Inc. · $112.32159 per ML · eff. 2026-09-23 filed
Other strengths, forms and brands
12 other products in the NADAC file share the FDA nonproprietary name cyclosporine with RESTASIS MULTIDOSE 0.05% EYE.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| CEQUA 0.09% SOLUTION | $10.38279 per EA filed | $9.33517 per EA filed |
| CYCLOSPORINE 0.05% EYE EMULSION | $0.90945 to $1.18033 per EA filed | $4.32927 per EA filed |
| CYCLOSPORINE 25 MG CAPSULE | $2.5957 per EA filed | $0.576 per EA derived |
| CYCLOSPORINE 100 MG CAPSULE | $7.50676 per EA filed | $1.455 per EA derived |
| CYCLOSPORINE MODIFIED 25 MG | $0.31377 per EA filed | $0.576 per EA derived |
| CYCLOSPORINE MODIFIED 50 MG | $0.76459 per EA filed | $0.7275 to $1.152 per EA derived |
| CYCLOSPORINE MODIFIED 100 MG | $1.23348 per EA filed | $1.455 per EA derived |
| CYCLOSPORINE MODIFIED 100 MG/ML | $2.03685 per ML filed | $1.455 per ML derived |
| GENGRAF 25 MG CAPSULE | $1.86549 per EA filed | $1.14257 per EA filed |
| NEORAL 25 MG GELATIN CAPSULE | $2.94566 per EA filed | $3.90784 per EA filed |
| NEORAL 100 MG GELATIN CAPSULE | $11.7731 per EA filed | $3.90784 per EA filed |
| RESTASIS 0.05% EYE EMULSION | $10.31247 to $10.31333 per EA filed | $10.19841 per EA filed |
| RESTASIS MULTIDOSE 0.05% EYE this page | $112.32159 per ML filed | $111.93625 per ML filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-02, 2026-07-08, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
What Medicare paid
Medicare Part D paid $615.65 for 5.5 mL, at an average of $111.93625 per ML in 2024 (2024-01-01 to 2024-12-31) for “Restasis Multidose” and “Cyclosporine”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 79,985 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 5.5 mL? Is it lower than what I would pay through my insurance?
- Is a generic version available, and would it suit me? NADAC lists a generic with the same ingredient, strength and dosage form by FDA: CYCLOSPORINE 0.05% EYE EMULSION. Ask your pharmacist or prescriber; do not switch on your own.
- How much is in the package I am getting? This page uses 5.5 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for RESTASIS MULTIDOSE 0.05% EYE labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Restasis Multidose / Cyclosporine: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
- Why does this page start at 5.5 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 5.5 mL in one package for this product’s NDC (“1 BOTTLE in 1 CARTON (0023-5301-05) / 5.5 mL in 1 BOTTLE”), so the card starts at one package: 5.5 ML. Change it to match your prescription.